Want to see HK:6896 full AI Analyst Report?
Golden Throat Holdings Group Co Ltd (6896) Price & Analysis
6896 Stock Chart & Stats
- Day’s Range
- HKD 1.95 - HKD 1.97
- 52-Week Range
- HKD 1.81 - HKD 3.80
- Previous Close
- HKD 1.95
- Volume
- 368.50K
- Average Volume (3M)
- 238.77K
- Market Cap
- HKD 1.44B
- Enterprise Value
- HKD 1.80B
- Total Cash (Recent Filing)
- HKD 1.08B
- Total Debt (Recent Filing)
- HKD 711.15M
- Price to Earnings (P/E)
- 5.8
- Beta
- 0.14
- Next Earnings
- Mar 31, 2027
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 17.44%
Bulls Say, Bears Say
Bulls Say
High, Durable Margins
Persistently high gross and net margins indicate strong pricing power and effective cost control in the core lozenge business. This profitability provides resilience against moderate demand changes and supports reinvestment, marketing, and shareholder returns over the next several quarters.
Recognized Branded Product
A recognized consumer-health brand can support repeat purchasing, retailer acceptance, and pricing discipline across established channels. The Golden Throat franchise gives the company a durable commercial foundation, rather than relying solely on undifferentiated commodity products.
Healthy Returns And Stable Assets
Healthy returns on equity combined with a stable asset base suggest the company has historically deployed its operating resources productively. This supports ongoing business viability and indicates that profitability is not dependent solely on rapid balance-sheet expansion.
Bears Say
Recent Revenue Contraction
The recent revenue decline shows that the company’s strong margins have not been matched by consistent top-line expansion. Repeated periods of contraction can limit operating leverage, reduce scale benefits, and make future earnings growth more dependent on pricing or product execution.
Sharp Cash-flow Deterioration
The steep year-over-year decline in operating and free cash flow weakens the company’s internally generated funding capacity. Even with strong accounting margins, sustained cash conversion is important for dividends, investment, and resilience, making this volatility a material fundamental concern.
Higher Leverage Reduces Flexibility
Although leverage remains described as manageable, the increase in debt-to-equity reduces financial flexibility if earnings or cash generation soften. Higher leverage can constrain capital allocation and leaves less balance-sheet capacity to absorb another period of weaker operating performance.
Golden Throat Holdings Group Co Ltd News
6896 FAQ
What was Golden Throat Holdings Group Co Ltd’s price range in the past 12 months?
What is Golden Throat Holdings Group Co Ltd’s market cap?
When is Golden Throat Holdings Group Co Ltd’s upcoming earnings report date?
How were Golden Throat Holdings Group Co Ltd’s earnings last quarter?
Is Golden Throat Holdings Group Co Ltd overvalued?
Does Golden Throat Holdings Group Co Ltd pay dividends?
What is Golden Throat Holdings Group Co Ltd’s EPS estimate?
How many shares outstanding does Golden Throat Holdings Group Co Ltd have?
What happened to Golden Throat Holdings Group Co Ltd’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Golden Throat Holdings Group Co Ltd?
What is the TipRanks Smart Score and how is it calculated?
Golden Throat Holdings Group Co Ltd Stock Smart Score
Company Description
Golden Throat Holdings Group Co Ltd
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China. Among its offerings are the widely recognized Golden Throat lozenges, an over-the-counter remedy designed to alleviate discomfort from sore and dry throats, as well as hoarseness often stemming from acute pharyngitis. The company further expands its Golden Throat lozenge line with products like Dule lozenges and their sugar-free counterparts, available in diverse flavors including orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, Golden Throat manufactures the Yinxingye tablet, formulated to enhance blood circulation, disperse blood stasis, and clear energy pathways. Its product portfolio also encompasses herbal vegetable beverages, crafted to provide vocal comfort and soothe irritated throats. Beyond its domestic market, the company extends its reach globally, exporting its range of products to countries and regions such as the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and across Africa. Established in 1956, Golden Throat Holdings Group Company Limited maintains its corporate headquarters in Liuzhou, within the People's Republic of China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yong Zeng
- Employees
- 824
- Website
- www.gxjsz.com
- Address
- CN
Golden Throat Holdings Group Co Ltd (6896) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 5 | 8 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 6 | 0 | 6 |








